Racura Oncology (RAC) AGM 2024 summary

Opening remarks and agenda

• Meeting opened with confirmation of quorum and proper constitution, followed by introductions of the board, management, and auditor.

• Agenda included the chair's address, formal business, and a CEO presentation.

Financial performance review

• Significant progress made in advancing RC220 towards clinical trials, including GMP manufacturing and GLP toxicology studies.

• Financial report for the year ended 30 June 2024 was presented, with the auditor available for questions.

• Share price recovered from below AUD 0.70 to around AUD 1.50, with prudent capital management and successful capital raise.

Board and executive committee updates

• Board renewal included retirement of two directors and appointment of Peter Smith as Executive Chair.

• Dr. Daniel Tillett became CEO and Managing Director; Dr. Serge Scrofani joined as Non-Executive Director, bringing strategic and commercialization expertise.

• Strengthened scientific and clinical advisory boards with notable appointments.